Next Article in Journal
Early Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol
Next Article in Special Issue
Effect of Dexamethasone on the Incidence and Outcome of COVID-19 Associated Pulmonary Aspergillosis (CAPA) in Critically Ill Patients during First- and Second Pandemic Wave—A Single Center Experience
Previous Article in Journal
Evaluation of 68Ga-Radiolabeled Peptides for HER2 PET Imaging
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 12
Issue 11
10.3390/diagnostics12112712
Review Report
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Invasive Aspergillosis in the Intensive Care Unit

Diagnostics 2022, 12(11), 2712; https://doi.org/10.3390/diagnostics12112712
by Liam Townsend 1 and Ignacio Martin-Loeches 1,2,3,*
Reviewer 2: Anonymous
Diagnostics 2022, 12(11), 2712; https://doi.org/10.3390/diagnostics12112712
Submission received: 18 October 2022 / Revised: 2 November 2022 / Accepted: 4 November 2022 / Published: 6 November 2022
(This article belongs to the Special Issue Diagnosis of Invasive Aspergillosis on ICU)

Round 1

Reviewer 1 Report

Your comprehensive and up-to-date review is very well written and deserves publication. I have no major comments.

Minor comments:

1)    You cited the reference stating that galactomannan (GM) from respiratory samples is considered superior to blood test in non-neutropenic patients (page 7, line 163), but quite often laboratories use assays validated for serum (cut-offs only for serum are provided). Could you comment on this subject and provide some advice how use these assays for respiratory samples? Could you signal in this part of the manuscript, that in COVID-19 serum samples are recommended, as you have written on page 11, lines 219-222? 

2)    The subheading “Conclusions” is lacking on page 15, between the lines 291 and 292.

Author Response

Please see the attached.

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript described invasive pulmonary aspergillosis (IPA). The diagnosis of IPA can be difficult in the intensive care unit (ICU). The authors showed the feature of IPA. The diagnosis of IPA and chemotherapy using foxmanogepix, ibrexafungerp, olorofim, or opelconazole were suggested. Thus, these findings will be useful for IPA. Therefore, the manuscript is not too excellent to be published after revision. In other words, the manuscript is so excellent that it should be published after revision.

 

Comments

(1) How many people died of IPA per year?

(2) Does chronic obstructive pulmonary disease (COPD) occur concurrently with infection of other germs than Aspergillus species? Influenza?

(3) Epithelial disruption allows for the translocation of Aspergillus into the surrounding tissues and bloodstream. When epithelial disruption is restored, will disease derived from IPA be cured?

(4) Are respiratory samples considered superior to blood tests, with respect to accuracy and/or simplicity?

(5) Did chemotherapy using foxmanogepix, ibrexafungerp, olorofim, or opelconazole exhibit good results for IPA without side effects? Will they be available clinically?

 

That is all.

Author Response

Please see the attached.

Author Response File: Author Response.pdf

Back to TopTop